Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

dimethyl glutamate

Deal Watch May 2016

Novartis, Quintiles and Sanofi are among those featured in this month’s round-up of pharma deal activity

Biogen Idec building

Biogen multiple sclerosis drug flunks clinical trial

Opicinumab had been proposed as a possible reparative therapy in MS

- PMLiVE

Biosimilar trastuzumab comparable to brand, ASCO hears

Roche’s Herceptin matched in safety and efficacy by Mylan and Biocon’s breast cancer drug

Free Thinking: Are biosimilars the answer to the rising cost of RA treatment?

In a past Free Thinking paper, we looked at the opportunity and challenges for biosimilar mAbs entering the rheumatoid arthritis market. A few years later and according to our Therapy...

Research Partnership

- PMLiVE

Sanofi Genzyme launches multiple sclerosis awareness campaign

Aims to highlight and address the physical and emotional burden of the disease

Biogen Idec building

Biogen and AbbVie bag FDA approval for multiple sclerosis drug

Once-monthly, self-administered Zinbryta ‘significantly’ reduces relapse rate

EU flag

Second Remicade biosimilar given green light in Europe

Samsung Bioepis’ Flixabi provides another lower-cost treatment option

Video: Global Biosimilars Market

Research director of Therapy Watch, Laurent Chanroux, discusses the growth opportunities for biosimilars and the importance of adaptable market tracking for pre and post product launch

Research Partnership

- PMLiVE

Pfizer split still on cards – for tax reasons

Firm continues to look for ways to reduce tax burden

Biogen Idec building

Biogen plans spin-out of haemophilia business

Aims to create two 'agile' specialist firms

It’s a digital hat trick for Pegasus as it scoops GOLD and two SILVERS at the PM Society Digital Awards 2016

Pegasus received three top accolades at the PM Society Digital Media Awards 2016, including gold for the highly acclaimed Craft: Best Innovation award with Biogen’s MS Explorer, and two silvers...

Evoke Mind+Matter

Roche - Basel

Cancer drugs help Roche beat expectations in first quarter

Sales of Avastin and Herceptin show no sign of slowing down

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links